HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer.
HONG KONG – Rigel Pharmaceuticals Inc. has joined forces with Japan's Kissei Pharmaceutical Co. Ltd. to develop and commercialize Rigel's small molecule inhibitor, Tavalisse (fostamatinib), in Japan, the Chinese mainland, Taiwan and South Korea for all potential indications.
HONG KONG – Rigel Pharmaceuticals Inc. has joined forces with Japan’s Kissei Pharmaceutical Co. Ltd. to develop and commercialize Rigel’s small molecule inhibitor, Tavalisse (fostamatinib), in Japan, the Chinese mainland, Taiwan and South Korea for all potential indications.
HONG KONG – China's Zhejiang Conba Pharmaceutical Co. Ltd. is working on a ¥960 million (US$138.3 million) plan to focus on foreign investment and take biosimilar maker Genor Biopharma Co. Ltd. public in Hong Kong.
HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients.
